Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Germ Cell and Embryonal » Neuroectodermal Tumors » Neoplasms, Neuroepithelial » Glioma » Astrocytoma » Glioblastoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Glandular and Epithelial » Neoplasms, Neuroepithelial » Glioma » Astrocytoma » Glioblastoma
Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Neoplasms, Nerve Tissue » Neuroectodermal Tumors » Neoplasms, Neuroepithelial » Glioma » Astrocytoma » Glioblastoma
Description
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures. MeSH
Hierarchy View
Approved Indicated Drugs (4)
Phase 4 Indicated Drugs (3)
Phase 3 Indicated Drugs (39)
Phase 2 Indicated Drugs (247)
fam-trastuzumab deruxtecan-nxki (Enhertu)
gsc-loaded autologous dendritic cells
hiv-gag mrna-pulsed autologous dcs
human cmv pp65-lamp mrna-pulsed autologous dcs
n-(4-hydroxyphenyl)all-trans retinamide
personalized neoantigen vaccine
Phase 1 Indicated Drugs (190)
allogeneic adipose derived mesenchymal stem cell
allogeneic natural killer cells
autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes
autologous chimeric switch receptor modified t cells
autologous dendritic cells pulsed with multiple neoantigen peptides.
autologous natural killer cells
carboxylesterase-expressing allogeneic neural stem cells
carcinoembryonic antigen-expressing measles virus
cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes
cd28-cd3zeta-cd19t-expressing car t cells
dec-205/ny-eso-1 fusion protein cdx-1401
dl-2-(difluoromethyl) ornithine
e. coli cd-expressing genetically modified neural stem cells
interferon gamma-1b (actimmune)
inverse correlated dual-target, truncated il7ra modified car -expressing autologous t-lymphocytes.
lu-177 labeled 6a10-fab-fragments
lutetium dotatate lu-177 (Lutathera)
neural stem cells-expressing crad-s-pk7
neural stem cells loaded with an oncolytic adenovirus
Other Experimental Indicated Drugs (25)
Organization Involved with Phase 3 Indications (119)
Association de Neuro-Oncologues d’Expression Francaise
Blokhin's Russian Cancer Research Center
Celilo Cancer Center at Mid-Columbia Medical Center
Chinese Academy of Medical Sciences
European Organisation for Research and Treatment of Cancer
french association of neuro-oncologists
Hannover Clinical Trial Center GmbH
ImmunoCellular Therapeutics, Ltd.
Justus Liebig University Giessen
Katholieke Universiteit Leuven
King Faisal Specialist Hospital
Mashhad University of Medical Sciences
National Cancer Institute (NCI)
National Institute of Neurological Disorders and Stroke (NINDS)
Radiation Therapy Oncology Group
Russian Foundation of Technological Development
Safe Save Medical Cell Sciences & Technology Co.,Ltd.
Shandong Lanjin Pharmaceuticals Co.,Ltd
Technical University of Dresden
The Serbsky State Scientific Center for Social and Forensic Psychiatry
Trans Tasman Radiation Oncology Group
University of California, Los Angeles
Organization Involved with Phase 2 Indications (374)
All India Institute of Medical Sciences
American Board for Transplant Certification
Assistance Publique - Hôpitaux de Paris
Badalona Hospital Germans Trias i Pujol
Beijing Tricision Biotherapeutics Inc
Bhagwan Mahaveer Jain Hospital
BioMimetix Pharmaceutical, Inc.
Biotech Pharmaceutical Co., Ltd.
BoYuan RunSheng Pharma (Hangzhou) Co., Ltd.
Brain Tumor Trials Collaborative
Carlo Besta Neurological Institute
Case Western Reserve University
Center for Neurosciences, Tucson
Centre Georges Francois Leclerc
Chittaranjan National Cancer Institute
City of Hope National Medical Center
Clinica Universidad de Navarra
Cooperative Trials Group for Neuro-Oncology
Cure Brain Cancer Foundation, Australia
Den-Mei Brain Tumor Education Foundation, Taichung, Taiwan
Developmental Therapeutics Consortium
Epitopoietic Research Corporation
Ever Supreme Bio Technology Co., Ltd.
Feinstein Institute for Medical Research
Florida Cancer Specialists, Sarasota
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Gan and Lee Pharmaceuticals, USA
German Federal Ministry of Education and Research
Guangzhou Trinomab Biotech Co., Ltd.
Gujarat Cancer & Research Institute
Heidelberg Clinical Research Centre
Hoag Memorial Hospital Presbyterian
Huazhong University of Science and Technology
Icahn School of Medicine at Mount Sinai
Institut National de la Santé Et de la Recherche Médicale, France
Istituto Nazionale per lo Studio e la Cura dei Tumori
Istituto Oncologico Veneto IRCCS
James Graham Brown Cancer Center
Jaslok Hospital and Research Centre, Mumbai, India
Medical University of South Carolina
Memorial Hermann Health System
Memorial Sloan-Kettering Cancer Center
Methodist Cancer Center, Houston, Texas
MultiCare Health System Research Institute
Nanxishan Hospital of Guangxi Zhuang Autonomous Region
National Cancer Institute, France
National Comprehensive Cancer Network
National Health and Medical Research Council, Australia
National Health Service, United Kingdom
National Institutes of Health (NIH)
Ningbo Yinzhou People's Hospital
North Central Cancer Treatment Group
Northern Sydney and Central Coast Area Health Service
Pediatric Brain Tumor Consortium
Shenzhen Geno-Immune Medical Institute
Specialized Medical Services, Oncology BV
State University of New York, Buffalo
The Christie NHS Foundation Trust
The University of Texas, Dallas
Translational Research Informatics Center, Kobe, Hyogo, Japan
Translational Research in Oncology
Triphase Research and Development Corporation
Universidad Complutense de Madrid
Universitair Ziekenhuis Brussel
Université catholique de Louvain
University Hospital Heidelberg
University Hospital of North Norway
University of Alabama, Birmingham
University of California, Davis
University of California, Irvine
University of California, San Diego
University of Colorado, Denver
University of Nice Sophia Antipolis
University of North Carolina at Chapel Hill
University of Southern Denmark
University of Texas, San Antonio
Virginia Commonwealth University
Organization Involved with Phase 1 Indications (96)
American Brain Tumor Association
American Lebanese Syrian Associated Charities
American Society of Clinical Oncology
Annias Immunotherapeutics, Inc.
Brain & Spine Surgeons of New York
Cancer and Leukemia Group B (CALGB)
Center Trials & Treatment Inc.
DRK Blutspendedienst Baden-Württemberg-Hessen gGmbH
Garnett McKeen Laboratory Inc.
Global Neurosciences Institute
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Hackensack University Medical Center
Ligue contre le cancer, France
LOEWE Center for Cell and Gene Therapy
Marino Biotechnology Co., Ltd.
Olivia Newton-John Cancer Research Institute
Oregon Health and Science University
Philadelphia College of Osteopathic Medicine
Shanghai Cell Therapy Research Institute
Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd
Organization Involved with Other Experimental Indications (14)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
